baber/WOPTO huggingface dataset:
Patent NZ-518931-A (NZ)
Title: Aminoheterocyclyamides as Pesticides and Antiparasitic Agents
Inventor: DUCRAY PIERRE
IPC: C07D409/12
Filed: 2000-11-30
Abstract: The invention relates to compounds of formula (I) in which R1, R2, R3, X1, X2 and X3 are as defined in claim 1, and to any enantiomers thereof. The active substances have advantageous pesticidal properties. They are particularly suitable for controlling pests in domestic and useful animals.
Patent NZ-519022-A (NZ)
Title: Fungal bioremediation
Inventor: WALTER MONIKA
IPC: B09C1/10
Filed: 2002-05-17
Abstract: A bioremediation agent comprising at least Trametes versicolor isolate selected from cultures A, B and C deposited as NM02/27875, NM02/27876 and NM02/27877 respectively. Also disclosed is the use of said bioremediation agent, a process for the bioremediation of contaminated soil, sawdust or other environmental samples and decontaminated, sawdust or other environmental sample produced by said process.
Patent NZ-520524-A (NZ)
Title: Method and apparatus for dispensing a liquid into a series of wells
Inventor: DE BEUKELEER WERNER RENE IRENE
IPC: G01N37/00
Filed: 2001-03-08
Abstract: The present invention relates to a method for adding a predetermined quantity of fluid from a reservoir, through a fluid outlet in fluid communication with said reservoir, into each well of at least one series of wells.
Patent NZ-521775-A (NZ)
Title: Improved luminescence characteristics detector
Inventor: VASIC MILAN
IPC: B44F1/12
Filed: 2002-01-26
Abstract: The invention discloses an improved method and a device implementing said method for the authentication of security documents or articles carrying luminescent marker compounds which show a time-deferred emission characteristic. The method allows a rapid extraction of characteristic luminescence parameters, such as emission intensity and time constants. The method is not sensitive to perturbations by ambient light and reduces the optical filtering requirements.
Patent NZ-522913-A (NZ)
Title: Valve with rotatable member providing interconnection of one external port each of at least three othe ports, with intermediate positions blocking flow
Inventor: ERIKSON TREVOR ALAN
IPC: F16K11/076
Filed: 2002-12-02
Abstract: Port 1 can be connected with any one of ports 2 to 5 by rotation of the hand lever. Flow is blocked as the lever is rotated between the inter-connections.
Patent NZ-525169-A (NZ)
Title: Spiroheterocyclic nitriles (amidino and guanidino peptidyl compounds) useful as reversible inhibitors of cysteine proteases
Inventor: BEKKALI YOUNES
IPC: C07D335/02
Filed: 2001-03-14
Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) where R1, R2, R3, R4, R5, R6, Het and X are as described in the specification. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
Patent NZ-527776-A (NZ)
Title: Checking integrity of transponder signal by comparison of data rate.
Inventor: URBAS DONALD J
IPC: A01K11/00
Filed: 2001-02-09
Abstract: A method for checking the integrity of a signal received from a transponder utilizing an accumulator comprising the steps of receiving a first data bit from a transponders, receiving a next data bit from a transponder, calculating the actual time elapsed between the last two successive data bits, subtracting an average time expected between data bits from the actual time between data bits to produce an error amount, adding the error to the accumulator, determining whether or not an accumulated value is greater than a predetermined error detection constant, and stop receiving transponder data bits if the accumulator value is greater than the error detection constant. (62) Divided out of 515161
Patent NZ-528638-A (NZ)
Title: Rapid soil drying
Inventor: RAJENDRAM GORDON SHANTHAKUMAR
IPC: G01N1/44
Filed: 2003-10-03
Abstract: Disclosed is a method for drying soil in preparation for analysis including the steps of: (a) increasing the surface area of the soil, such as by using a soil crusher device, (b) forcing a gas through the soil wherein the gas, such as hot air, is not readily reactive with the soil, and (c) subjecting the soil to an elevated temperature that does not exceed approximately 50°C. Also disclosed is an assembly for drying soil, when used in the above method, comprising a gas supply device, capable of forcing gas that is not readily reactive through a soil sample, and a heating element capable of subjecting the soil to an elevated temperature.
Patent NZ-533590-A (NZ)
Title: Easy-open container end
Inventor: OLSON CHRISTOPHER J
IPC: B21D51/46
Filed: 2002-11-27
Abstract: The disclosed invention describes a container end that 300 can be easily opened and does not rely on a conventional metal tab, riveted onto the end, thereby avoiding the problems and the cost associated with such a tab. The invention utilizes a traditional container end shell with a separate and distinct piece that is formed independently and is inserted into a countersink 302 which is placed on the outer surface of the container end shell. The removal of this separate piece exerts a force or causes a change in the properties of the container wall in the countersink area, initiating and proliferating a discontinuity in the container wall, thereby creating an opening in the container. This change in the properties of the container wall can be mechanical, chemical, thermal or any other modality, which has the ability to influence the integrity of the container wall.
Patent NZ-533843-A (NZ)
Title: Orodispersible pharmaceutical composition comprising agomelatine
Inventor: WUTHRICH PATRICK
IPC: A61K31/165
Filed: 2003-01-22
Abstract: A solid orodispersible pharmaceutical composition of agomelatine is disclosed, wherein the composition comprises agomelatine and granules consisting of co-dried lactose and starch. This solid orodispersible pharmaceutical composition is suitable for use in the treatment of depression, sleep disorders and pathologies associated with deregulation of circadian rhythms.
Patent NZ-546645-A (NZ)
Title: 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors
Inventor: MOUSSY ALAIN
IPC: C07D413/14
Filed: 2004-10-22
Abstract: The disclosure relates to 2-aminoaryloxazole compounds of formula (I) that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit, bcr-abl, FGFR3 and/or Flt-3 inhibitors.
Patent NZ-550150-A (NZ)
Title: Synergistic attenuation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof
Inventor: CLARKE DAVID KIRKWOOD
IPC: A61K39/00
Filed: 2005-04-05
Abstract: Disclosed is a genetically modified vesicular stomatitis virus (VSV) comprising at least two different classes of mutations in its genome, wherein the two mutations are selected from (i) a truncated G gene mutation and an N gene shuffling mutation; (ii) a truncated G gene mutation and a non-cytopathic M gene mutation, wherein the non-cytopathic M gene mutation is a mutation at methionine 33 and methionine 51 of the M gene; or (iii) a G stem mutation and a gene shuffling mutation, wherein the two mutation synergistically attenuate VSV pathogenicity.
Patent NZ-550462-A (NZ)
Title: Low-calorie food bar
Inventor: COLEMAN EDWARD C
IPC: A23L33/00
Filed: 2006-10-11
Abstract: Provided is a food bar having less than 1 10 Cal/28g serving, comprising: a core component comprising, as a unitary matrix, protein crisps, caramel, water soluble dietary fibers, and binder material; a caramel component comprising water-soluble dietary fibers; and a compound coating applied to surface portions of the core component and caramel component, wherein the food bar comprises about 5 to about 30 wt% water-soluble dietary fibers. Further provided are methods of producing such food bars.
Patent NZ-550600-A (NZ)
Title: Epitopes related to coeliac disease
Inventor: BEISSBATH TIM
IPC: A23L7/10
Filed: 2005-04-28
Abstract: Disclosed are epitopes useful in methods of diagnosing, treating, and preventing coeliac disease. The epitopes are selected from the group consisting of transglutaminase-deamidated SEQ ID NOs: 1787-1829 and functional equivalents thereof. Also disclosed are mutant gluten proteins modified by a transglutaminase, and plants and foods expressing these mutant proteins.
Patent NZ-551781-A (NZ)
Title: Methods for determining conformational changes and self-assembly of proteins
Inventor: NILSSON PETER
IPC: G01N33/68
Filed: 2005-02-22
Abstract: Disclosed is a method for detecting self-assembly/aggregation in a protein, having the ability to self-assemble/aggregate, using a conjugated polyelectrolyte as a direct probe, comprising the steps: a. bringing said conjugated polyelectrolyte in direct contact with said protein by exposing the conjugated polyelectrolyte to the protein; b. detecting a change in at least one property of the conjugated polyelectrolyte; c. using said change to determine a self-assembly/aggregation in said protein, wherein the self-assembly/aggregation is the formation of amyloid fibrils or protofibrils.
Patent NZ-553000-A (NZ)
Title: Switching technique for efficient electrical power utilization
Inventor: SIRAJUDDIN MOHAMED
IPC: G01R25/04
Filed: 2007-02-02
Abstract: A phase angle correction circuit for an AC supply is provided. The circuit consists of a phase angle detection circuit repetitively detecting the difference in phase between voltage and current of the AC supply, a counter circuit whose peak count is a function of the prevailing phase angle detected, and a switchable reactance bank. At least some of the reactances in the bank are connectable across the power supply based on the peak count reached by the counter.
Patent NZ-561005-A (NZ)
Title: New isothiazoloquinolones and related compounds as anti-infective agents
Inventor: BRADBURY BARTON JAMES
IPC: A61K31/4365
Filed: 2006-02-15
Abstract: Disclosed are 9-cyclopropyl-isothiazolo[5,4-b]quinoline-3,4(2H,9H)-diones and 9-cyclopropyl-isothiazolo[1,8]naphthyridine-3,4(2H,9H)-diones having formula I, which are useful for the manufacture of a medicament for treating a bacterial or protozoal infection such as a urinary tract infection, pyelonephritis, lower respiratory tract infection, skin infection, skin-structure infection, urethral gonococcal infection, cervical gonococcal infection, urethral chlamydial infection, cervical chlamydial infection, bone infection, joint infection, gram-negative bacterial infection, infectious diarrhoea, typhoid fever, prostatitis, acute sinusitis, acute exacerbation of chronic bronchitis, pneumonia, intra-abdominal infection, gynecologic or pelvic infection.
Patent NZ-563603-A (NZ)
Title: A method for producing stem cells or stem cell-like cells from mammalian embryos
Inventor: VASSILIEV IVAN
IPC: C12N5/0735
Filed: 2006-04-28
Abstract: Provided is a method of producing functional stem cells or stem cell-like cells comprising culturing a non-human embryo or primary embryonal outgrowth from said embryo in the presence of a demethylation agent and isolation functional pluripotent cells. Further provided are corresponding stem cell isolation media comprising a demethylation agent.
Patent NZ-563726-A (NZ)
Title: Heat pump system and method for heating a fluid
Inventor: YOU YING
IPC: F24H4/02
Filed: 2006-05-18
Abstract: A heat pump system for heating a fluid 6, the system including an evaporator 1 for extracting heat from a heat source 3 to vaporise a refrigerant, a compressor 4 fluidly connected to the evaporator 1 for compressing the refrigerant vapour, a condenser 5 fluidly connected to the compressor 4 for transferring heat from the compressed refrigerant to the fluid 6, a main expansion device 8 fluidly connecting the condenser 5 to the evaporator 1 for reducing the temperature of the refrigerant, means for diverting and reducing the temperature of a portion of the refrigerant from the condenser 5, and means 9 for fluidly injecting the temperature reduced refrigerant portion into the compressor 4 such that the temperature reduced refrigerant portion mixes with the refrigerant vapour at an intermediate pressure and induces at least quasi-two stage compression of the refrigerant vapour and the refrigerant portion for discharge into the condenser 5.
Patent NZ-566277-A (NZ)
Title: A method of making heat cells comprising exothermic compositions having absorbent gelling material
Inventor: WONG VINCENT YORK-LEUNG
IPC: F24V30/00
Filed: 2006-09-22
Abstract: A method of making a heat cell comprising a particulate exothermic composition, wherein the method comprises the steps of: (a) constructing a particulate premix composition having a premix cell weight of from 0.4 grams to 2.5 grams, wherein the particulate premix composition comprises: (i) from 10 percent to 90 percent by weight of iron powder; (ii) from 1 percent to 25 percent by weight of a carbon selected from the group consisting of activated carbon, non-activated carbon, and mixtures thereof; (iii) from 1 percent to 25 percent by weight of an absorbent gelling material; and (iv) from 1 percent to 10 percent by weight of water, wherein the median particle size ratio of absorbent gelling material to iron powder is from about 3:1 to about 1:3, and (b) dosing a brine solution onto the pre-mix composition. Also disclosed is the heat cell obtained by said method.
Patent NZ-575030-A (NZ)
Title: Histone deacetylase inhibitors with combined activity on class-I and class-IIb histone deacetylases in combination with proteasome inhibitors
Inventor: ARTS JANINE
IPC: A61P35/00
Filed: 2007-09-11
Abstract: Disclosed is a combination of a proteasome inhibitor wherein said proteasome inhibitor is bortezomib and a histone deacetylase inhibitor wherein said histone deacetylase inhibitor is compound No. 1a the pharmaceutically acceptable acid or base addition salts and the stereochemically isomeric forms thereof for the treatment of acute lymphoblastic leukemia, acute myelogenous leukemia, acute promyelocytic leukemia, acute myeloid leukemia, acute monocytic leukemia, lymphoma, chronic B cell leukemia, chronic myeloid leukemia, chronic myeloid leukemia in blast crisis, Burkitt's lymphoma and multiple.
Patent NZ-575255-A (NZ)
Title: Environmental monitor, sensors thereof, and/or power management system
Inventor: LUCINSKY DARREN
IPC: G01W1/02
Filed: 2006-06-20
Abstract: A device including a power management system is disclosed. The device comprises: a circuit including a connection for a power source, a connection for a load, a connection for a first electrical storage battery, a connection for a second electrical storage battery and switches for selectively: - connecting each storage battery connection to the power source connection in a circuit where current may only flow to the battery connection when the battery connection is connected to a power source connection; or - connecting each storage battery connection to the load connection in a circuit in which current may only flow from the battery connection when the battery connection is connected to the load connection. The device also includes a controller programmed to select a battery to be on load and a battery to be on charge, and to provide output signals to the switches to connect the connections for the battery on load to the load connection and not to the power source connection, and to connect the battery on charge to the power source connections and not to the load connection. If the battery on charge has immediately prior been a battery on load, the controller will connect the battery on load to the load connection before disconnecting the battery on charge from the load connection.
Patent NZ-576484-A (NZ)
Title: Piperidinylamino-pyridazines and their use as fast dissociating dopamine 2 receptor antagonists
Inventor: MACDONALD GREGOR JAMES
IPC: A61K31/501
Filed: 2007-12-05
Abstract: Disclosed are piperidinylamino pyridazine compounds of formula I where the variables are described in the disclosure. The compounds a suitable for use as dopamine 2 receptor antagonists and antipsychotics. Also disclosed is the process for making compounds of formula I and the use of the compounds in making a medicatment to treat a number of antipsychotic disorders such asschizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, substance-induced psychotic disorder, psychotic disorder not otherwise specified, psychosis associated with dementia, major depressive disorder, dysthymic disorder, premenstrual dysphoric disorder, depressive disorder not otherwise specified, Bipolar I disorder, bipolar II disorder, cyclothymic disorder, bipolar disorder not otherwise specified, mood disorder due to a general medical condition, substance-induced mood disorder, mood disorder not otherwise specified, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, acute stress disorder, post-traumatic stress disorder, mental retardation, pervasive developmental disorders, attention deficit disorders, attention-deficit/hyperactivity disorder, disruptive behaviour disorders, personality disorder of the paranoid type, personality disorder of the schizoid type, personality disorder of the schizotypical type, tic disorders, Tourette's syndrome, substance dependence, substance abuse, substance withdrawal, trichotillomania.
Patent NZ-579280-A (NZ)
Title: Mask assembly
Inventor: DAVIDSON AARON SAMUEL
IPC: A61M16/06
Filed: 2008-05-12
Abstract: The portion R between the ends of the at least two elongate members of the neck that joins the frame 10 of a mask assembly to the forehead support assembly 25 converge at a point proximal to between the eyes of the patient wearing the mask.
Patent NZ-588435-A (NZ)
Title: Use of a polypeptide with an angiotensin-converting enzyme 2 (ACE2) activity for treating tumours (with the exception of lung cancer)
Inventor: JANZEK-HAWLAT EVELYNE
IPC: A61K38/48
Filed: 2009-04-07
Abstract: Use of a recombinant soluble form of human angiotensin-converting enzyme 2 (ACE2) for the production of a medicament for the treatment of tumour diseases, with the exception of lung cancer.
Patent NZ-594157-A (NZ)
Title: Sulfonamide compounds for the treatment of respiratory disorders
Inventor: RAMDAS VIDYA
IPC: A61K31/415
Filed: 2009-12-23
Abstract: 594157 Disclosed are benzenesulfonamide compounds of formula (I) where the substituents are as disclosed in the specification. Examples of compounds of formula (I) are: 2,4-Dichloro-N-[4-(1-p-tolyl-1H-pyrazol-4-yloxy)-phenyl]-benzenesulfonamide; 2,4-Dichloro-N-{ 3-chloro-4-[1-(4-chloro-3-trifluoromethyl-phenyl)-1H-pyrazol-4-yloxy]-phenyl} -benzenesulfonamide; 2,4-Dichloro-N-{ 3,5-dichloro-4-[1-(2,4-difluoro-phenyl)-1H-pyrazol-4-yloxy]-phenyl} -benzenesulfonamide. Also disclosed are pharmaceutical compositions comprising the compounds and the use of the compounds in the manufacture of a medicament for the treatment of respiratory disease.
Patent NZ-595764-A (NZ)
Title: Whey or raw milk demineralisation and fractionation
Inventor: SCOTT STEPHEN NIALL
IPC: A23L33/00
Filed: 2010-03-17
Abstract: Provided is a process for the demineralisation and fractionation of whey or raw milk comprising the steps of: a) subjecting the whey or raw milk to ultrafiltration to provide a retentate fraction and a whey permeate; b) concentrating the whey permeate to nanofiltration to provide a concentrated lactose rich retentate; c) subjecting the nanofiltration retentate to ion permeation chromatography at elevated temperatures of between 50 degree C and 80 degree C, using an appropriate resin; and d) eluting the nanofiltration retentate in various fractions from the resin using water as the eluant.
Patent NZ-603175-A (NZ)
Title: Modulators of fatty acid amide hydrolase
Inventor: KEITH JOHN M
IPC: A61K31/496
Filed: 2011-05-02
Abstract: 603175 4-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide is described, which is useful as a FAAH modulator. 4-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). A method of synthesizing 4- (2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1 -carboxylic acid (4- chloro-pyridin-3-yl)-amide is also disclosed. Hydrochloride salts of 4-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide particularly the bis-hydrochloride are also disclosed.
Patent NZ-603230-A (NZ)
Title: Nitrogen containing heteroaryl compounds
Inventor: KUHN BERND
IPC: A61K31/506
Filed: 2011-06-06
Abstract: Disclosed herein are nitrogen containing heteroaryl compounds of general formula (I), wherein the substituents are as defined within the specification, processes for their preparation, compositions comprising said compounds and uses thereof. Said compounds are useful in the treatment or prophylaxis of psychotic disorders, schizophrenia, positive, negative and/or cognitive symptoms associated with schizophrenia, delusional disorder, substance-induced psychotic disorder, anxiety disorders, panic disorder, obsessive/compulsive disorders, acute stress disorder, generalized anxiety disorder, drug addictions, movement disorders, Parkinson's disease, restless leg syndrome, cognition deficiency disorders, Alzheimer's disease, multi-infarct dementia, mood disorders, depression, bipolar disorders, neuropsychiatric conditions, psychosis, attention-deficitihyperactivity disorder, attentional disorders, diabetes and related disorders, type 2 diabetes mellitus, neurodegenerative disorders, Huntington's disease, multiple sclerosis, stroke, spinal cord injury, solid tumors, hematological malignancies, renal cell carcinoma or breast cancer. Particularly preferred compounds include: 6-Cyclopropyl-N-(4-cyclopropylcarbamoyl-pyridin-3-yl)-3-(pyrimidin-5-ylamino)-pyridine-2-carboximidic acid, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (2,3-difluoro-6-methylcarbamoyl-phenyl)-amide, 3-(Pyrimidin-5-ylamino)-6-(tetrahydro-furan-3-yl)-pyrazine-2-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 2-Isopropyl-5-(pyrimidin-5-ylamino)-pyrimidine-4-carboxylic acid (1-methyl-3-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-Morpholin-4-yl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-Azetidin-1-yl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (1-methyl-5-methylcarbamoyl-lH-pyrazol-4-yl)-amide.